Health

ACT-Accelerator: the next 12 months

October 31, 2021

Global

EIU COVID-19 Health Funding Tracker

October 31, 2021

Global
Anelia Boshnakova

Senior information specialist, Health Policy and Clinical Evidence

Anelia is a senior information specialist and health policy analyst in the Health Policy and Clinical Evidence team. Her areas of expertise are evidence-based medicine and health policy and systems research. Before joining the EIU, Anelia worked as a senior information specialist at Bazian, and previously at University College London Hospitals NHS Foundation Trust. Anelia holds a master’s degree in Library and Information Science from Syracuse University.

Contact

An independent review of the international initiative provides some insights about its challenges, achievements, and directions for the future reflected in the new ACT-A strategic plan

The was launched in April 2020 as a voluntary partnership of global health organisations with the goal to speed up progress in the development and roll out of key medical countermeasures.

Earlier this month, an of the ACT-Accelerator initiative highlighted some of its successes as well as the external and internal challenges that impeded the achievement of its objectives in the past 18 months. The main external challenges the global collaboration faced were the constraints in product supply in the context of complex geopolitical tensions and domestic-focused responses in many parts of the world. The report also made some forward-looking recommendations to support achieving the ACT-A main objectives to close the current equity gap in COVID-19 tools and ensure that recipient countries play an active role in shaping ACT-A activities.

These recommendations are reflected in the published on 28 October 2021. The plan sets out urgent actions to address critical gaps in access to COVID-19 tests, treatments, vaccines, and personal protective equipment in low- and middle-income countries. To implement this plan, the ACT-Accelerator needs of US$23.4 billion until September 2022. The breakdown of the budget across is as follows:

  • US$7.0 billion for diagnostics
  • US$7.0 billion for vaccines
  • US$3.5 billion for therapeutics
  • US$5.9 billion for the Health Systems & Response Connector

It is estimated that will not only help to reach globally agreed targets for COVID-19 tools but will also “prevent at least 5 million potential additional deaths, save the global economy more than US$5.3 trillion, and accelerate the end of the pandemic everywhere.”

 

For more information see our .

For all our blog posts, see our .

 

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week